Why extractables and leachables (E&L) matter in stability:

Extractables are compounds that can be released from packaging materials under aggressive conditions, while leachables are those that migrate into the product under actual storage conditions. When left unchecked, these compounds can compromise drug purity, potency, and safety. E&L testing during stability ensures the container-closure system does not negatively impact product quality over time.

When is E&L testing required during stability?

E&L testing becomes essential when the product is a biologic, parenteral, inhalation drug, or uses novel packaging materials like multi-layered plastics or rubber stoppers. It’s also necessary if degradation trends suggest chemical migration, or if prior extractables studies identified high-risk substances. Failure to include E&L when indicated may result in regulatory queries or delayed approval.

Regulatory and Technical Context:

ICH Q3E and global regulatory expectations:

ICH Q3E specifically addresses the need for leachable testing when a risk of interaction exists. US FDA, EMA, Health Canada, and WHO TRS 1010 emphasize container-closure system integrity and its effect on product stability. CTD Module 3.2.P.7 must describe the packaging and any relevant E&L data. Leachables are often tracked as part of long-term and accelerated stability to assess cumulative impact over time.

Audit readiness and submission significance:

During inspections, regulators expect evidence that leachable risks have been considered. If data is missing or if leachable spikes are observed without explanation, the product may face shelf-life limitations or post-approval testing requirements. Submissions should include E&L summaries in Modules 3.2.P.5.5 and 3.2.P.8.3, especially for high-risk dosage forms.

Best Practices and Implementation:

Conduct extractables studies before initiating stability:

Perform a thorough extractables study using aggressive solvents and elevated conditions to identify potential leachable candidates from packaging materials. Use multiple analytical techniques (e.g., GC-MS, LC-MS, ICP-MS) and maintain a database of compounds with chemical identities, retention times, and toxicological thresholds.

This data forms the basis for targeted leachables monitoring during stability.

Integrate leachables testing into your stability protocol:

Include specific test parameters in the protocol for high-risk time points (e.g., 6, 12, 24 months) or storage conditions (e.g., 40°C/75% RH). Monitor for known leachables using validated methods with sensitivity below the safety thresholds. Define action limits, reporting levels, and OOS criteria in alignment with toxicological risk assessments (e.g., TTC or PDE).

Apply bracketing strategies where packaging material variants are used and ensure that test frequency is justified in the protocol.

Document results clearly and act on findings:

Include E&L results in the final stability reports and trend them alongside physical, chemical, and microbial attributes. Highlight any upward trends, correlate with extractables profile, and initiate risk assessments if thresholds are breached. Use these insights to adjust packaging, revise specifications, or initiate toxicological reviews as needed.

Maintain traceability between E&L results, stability conditions, and packaging lots in both regulatory submissions and internal audits.

Why visual inspection is critical in container-closure systems:

Visual assessment of packaging components is often the first indicator of underlying chemical instability or material interaction. Discoloration of caps, seals, stoppers, or vial interiors may signal oxidation, leachables migration, UV damage, or reactions between the product and packaging. Regular inspection of container-closure systems throughout stability ensures that these warning signs are not overlooked.

Potential causes of discoloration:

Color changes may result from multiple mechanisms including light exposure, polymer degradation, residual solvents, or API-excipient interactions. For instance, rubber stoppers may turn yellow or brown due to oxidation of antioxidants or sulfur cross-linkers. HDPE bottles may discolor if exposed to elevated humidity and heat. These issues, if not detected early, can escalate into product recalls or regulatory observations.

Regulatory and Technical Context:

ICH, WHO, and GMP expectations:

ICH Q1A(R2) requires evaluation of product appearance and packaging integrity during stability. WHO TRS 1010 emphasizes the importance of visually inspecting the container-closure system at each time point. GMP guidelines (e.g., 21 CFR Part 211.94, EU Annex 9) mandate the use of non-reactive, non-additive packaging and visual examination for defects or anomalies during routine testing.

Regulatory risk and documentation standards:

Auditors often review photographic records and visual inspection logs. If packaging discoloration is detected during a study or in the field without prior documentation or justification, it may trigger data integrity concerns or questions about compatibility testing. Discoloration may also suggest extractables/leachables concerns, especially for parenteral and inhalation products.

Best Practices and Implementation:

Include visual checks at every stability time point:

As part of each pull schedule, inspect all components—caps, stoppers, seals, labels, internal vial surfaces—for any discoloration or surface change. Document findings with photographs and descriptions. Compare with baseline images taken at time zero to detect subtle but progressive changes. Train analysts to recognize early signs and classify severity levels.

Include visual appearance as a separate parameter in your stability data summary and review any abnormal observations through QA.

Link discoloration to root cause analysis and mitigation:

If discoloration is observed, conduct a detailed investigation involving analytical testing of the affected areas. This may include FTIR, GC-MS for volatiles, or UV-Vis scanning. Determine whether the discoloration impacts product quality or originates from the environment, formulation, or packaging. Implement CAPA if issues are systemic or batch-specific.

Requalify packaging vendors if material inconsistencies are found or initiate extractable/leachable studies as required.

Reflect findings in protocol and regulatory documentation:

Include observations and their impact analysis in CTD Module 3.2.P.8.1 (Stability Summary) and highlight preventive measures in 3.2.P.7 (Container Closure). If discoloration is non-impactful but frequent, consider documenting it in labeling to manage visual expectations. Ensure that any such observations are traceable, risk-assessed, and clearly explained during audits.

What is label or ink migration in packaging:

Label migration refers to the transfer of chemicals—particularly inks, adhesives, and coatings—from printed packaging materials into the pharmaceutical product. This is a concern when the product is stored in direct contact with printed surfaces, such as blisters, pouches, or sachets without internal barriers.

Migrated substances can contaminate the formulation, alter its appearance or odor, and potentially create toxicity or efficacy risks.

Why migration testing is crucial for stability:

During long-term stability, especially under elevated temperature or humidity, label constituents may migrate at an accelerated rate. Without prior testing, companies risk discovering this issue late in development—forcing costly packaging changes or product recalls.

This tip emphasizes proactive compatibility assessments during packaging qualification to ensure product integrity throughout shelf life.

Real-world consequences of overlooking label migration:

Undetected migration has led to regulatory alerts, market withdrawals, and damaged reputations in pharmaceutical and nutraceutical sectors. Migration-related failures have included solvent leaching into oral solutions, discoloration in tablets, or adhesive odors permeating through sachets.

Regulatory and Technical Context:

ICH, FDA, and EU expectations:

ICH Q1A(R2) and Q3C highlight the need to assess the compatibility of drug products with their packaging. EU GMP Annex 9, FDA container closure guidance, and EMA packaging material guidelines specifically mandate migration assessments when printed components contact dosage forms.

Agencies expect label migration risks to be addressed in CTD Module 3.2.P.7 (Container Closure System), supported by studies or justification.

Migration-related compliance risks:

During regulatory inspections, auditors review whether migration was evaluated for contact-sensitive packaging. Absence of such data—especially for low-permeability plastics or solvent-based inks—can result in compliance observations or submission deficiencies.

Migration is also increasingly scrutinized in pediatric formulations, inhalation products, and high-exposure dosage forms.

Best Practices and Implementation:

Assess product-packaging contact risk:

Identify all instances where the product is in direct contact with printed surfaces—especially in unit-dose forms, powders in sachets, or semi-solids in printed tubes. Consider the presence of volatile solvents, hydrophilic excipients, or permeable matrices that may accelerate migration.

Categorize packaging types by risk level and prioritize high-risk configurations for formal migration studies.

Design and conduct migration studies:

Place placebo or representative product samples in contact with printed packaging under ICH stability conditions (e.g., 25°C/60% RH or 40°C/75% RH). Analyze for potential migrants such as ink components, plasticizers, or adhesives using GC-MS, LC-MS, or headspace analysis techniques.

Compare results against toxicological thresholds and determine whether migration is within acceptable safety limits.

Validate packaging materials and establish controls:

If migration is detected but within safe limits, include data in your CTD and define usage duration and storage conditions accordingly. If excessive migration occurs, switch to barrier layers (e.g., unprinted liners or foil lamination) or reformulate ink systems.

Ensure all packaging vendors provide toxicological clearance and material safety certificates for inks, adhesives, and substrates used in pharmaceutical contact layers.